Severe trachomatous dry eye treatment

Article

Dr Mustafa Guzey and colleagues have found topical cyclosporine A to be effective in treating severe trachomatous dry eye in a recent study published in Clinical & Experimental Ophthalmology.

Dr Mustafa Guzey and colleagues have found topical cyclosporine A to be effective in treating severe trachomatous dry eye in a recent study published in Clinical & Experimental Ophthalmology.

In an author commentary published on MDLinx Dr Guzey confirmed that whilst there is no therapeutic treatment available at the moment for severe trachomatous dry eye: "In preliminary studies, treatment with topical CsA improved the signs and the symptoms of dry eye syndrome. An increase in goblet cell counts was reported in association with clinical improvement. Reduced numbers of activated T lymphocytes in conjunctiva and a decrease in IL's in conjunctival epithelium were also observed. CsA significantly improved corneal staining, Schirmer scores and significantly increased conjunctival goblet cell density."

Sixty four patients were included in the study and 32 were treated with CsA 0.05% ophthalmic emulsion twice daily and concomitant 5 times daily non-preserved artificial tear and the other 32 were designated as the control group receiving placebo emulsion twice daily and non-preserved artificial tear 5 times daily.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.